Search hospitals > California > Riverside
Kaiser Permanente-Riverside
Claim this profileRiverside, California 92505
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Recurrence
143 reported clinical trials
8 medical researchers
Summary
Kaiser Permanente-Riverside is a medical facility located in Riverside, California. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Kaiser Permanente-Riverside is involved with conducting 143 clinical trials across 344 conditions. There are 8 research doctors associated with this hospital, such as Helen H. Moon, Gary L. Buchschacher, Eric C. McGary, and Ashraf R. Aziz.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage II
Stage III
Top PIs
Helen H. MoonKaiser Permanente-Riverside7 years of reported clinical research
Studies Cancer
Studies Tumors
13 reported clinical trials
23 drugs studied
Gary L. BuchschacherKaiser Permanente-Anaheim6 years of reported clinical research
Studies Colorectal Cancer
Studies Cancer
12 reported clinical trials
33 drugs studied
Eric C. McGaryKaiser Permanente-Fontana9 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
10 reported clinical trials
18 drugs studied
Ashraf R. AzizKaiser Permanente-Baldwin Park5 years of reported clinical research
Studies Lymphoma
Studies Leukemia
10 reported clinical trials
30 drugs studied
Clinical Trials running at Kaiser Permanente-Riverside
Non-Small Cell Lung Cancer
Lung Cancer
Breast Cancer
Prostate Cancer
Diffuse Large B-Cell Lymphoma
Cancer
Lymphoma
Colorectal Cancer
Small Intestinal Adenocarcinoma
Anal Squamous Cell Carcinoma
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This study is evaluating whether the addition of a drug to chemotherapy may help treat non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Ramucirumab + Pembrolizumab vs Chemotherapy
for Non-Small Cell Lung Cancer
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if giving ramucirumab with pembrolizumab is more effective at treating patients with stage IV or recurrent non-small cell lung cancer than standard chemotherapy.
Recruiting2 awards Phase 310 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This study is evaluating whether a drug called crizotinib may help treat patients with non-small cell lung cancer.
Recruiting2 awards Phase 328 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Kaiser Permanente-Riverside?
Kaiser Permanente-Riverside is a medical facility located in Riverside, California. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Kaiser Permanente-Riverside is involved with conducting 143 clinical trials across 344 conditions. There are 8 research doctors associated with this hospital, such as Helen H. Moon, Gary L. Buchschacher, Eric C. McGary, and Ashraf R. Aziz.